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Abstract
Characterizing and monitoring tumor genomes with blood samples could achieve significant improvements in precision
medicine. As tumors shed parts of themselves into the circulation, analyses of circulating tumor cells, circulating tumor
DNA, and tumor-derived exosomes, often referred to as “liquid biopsies”, may enable tumor genome characterization by
minimally invasive means. Indeed, multiple studies have described how molecular information about parent tumors can
be extracted from these components. Here, we briefly summarize current technologies and then elaborate on emerging
novel concepts that may further propel the field. We address normal and detectable mutation levels in the context of our
current knowledge regarding the gradual accumulation of mutations during aging and in light of technological
limitations. Finally, we discuss whether liquid biopsies are ready to be used in routine clinical practice.
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Background
As the concept of precision medicine in the field of cancer
management continues to evolve, so too do the challenges
and demands with regards to diagnosis, prognosis, and
prediction of treatment resistance [1, 2]. Although the dis-
covery of molecular agents able to target specific genomic
changes in metastatic cancer patients has revolutionized
patient care, tumor heterogeneity remains a daunting obs-
tacle for clinicians who need to optimize therapy regimens
based on an individual’s cancer genome [3]. Tissue biop-
sies, which still currently represent the standard of tumor
diagnosis, unfortunately only reflect a single point in time
of a single site of the tumor. Such a sampling method is
thus inadequate for the comprehensive characterization of
a patient’s tumor, as it has been demonstrated that various
areas within the primary tumor or metastases can in fact
harbor different genomic profiles [4]. The molecular gen-
etic diversity within a tumor can also alter over time, thus
rendering future treatment decisions based on historical
biopsy information potentially inaccurate and suboptimal
[5, 6]. Furthermore, a surgical biopsy procedure is
hampered by limited repeatability, patient age and comor-
bidity, costs, and time, potentially leading to clinical com-
plications. Despite these ongoing clinical issues, the
advent of next-generation sequencing (NGS) technologies
has proven its value in the search for novel, more compre-
hensive and less invasive biomarkers in order to truly
realize the goals of cancer precision medicine [1].
Such minimally invasive tests, known as a “liquid biop-
sies” [7, 8], have gained plenty of traction in the last few
years and the method was even recently listed as a top ten
technology breakthrough in 2015 by the MIT Technology
Review (www.technologyreview.com/s/544996/10-break-
through-technologies-of-2015-where-are-they-now/). One
strategy of this approach takes advantage of circulating
free DNA (cfDNA) found in the plasma component of
blood to evaluate the current status of the cancer genome.
Since the discovery of the existence of cfDNA in 1948, nu-
merous research efforts have attempted to harness this
easily accessible and rich genetic information in the ci-
rculation of cancer patients. Furthermore, other co-
mponents, such as circulating tumor cells (CTCs) or
exosomes, have been intensively investigated. Herein, we
briefly summarize the current technologies and applica-
tions, the detection rates in the context of the number of
mutations that is normal for healthy individuals depend-
ing on their age, and the new technologies and emerging
concepts as well as existing challenges for liquid biopsy
applications. Finally, we will present our view as to when
the information from liquid biopsies will be reliable and
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Current technologies and applications
Here, we refer to technologies as “current” if they can be
viewed as established approaches reflected in several
publications describing their applicability. In contrast,
“emerging technologies” are novel ideas and concepts
for which proof-of-concepts or only a few applications
have been published. Current technologies applied in
liquid biopsy research have been extensively reviewed
[9–12] and we have therefore only briefly summarized
them herein.
Circulating tumor DNA (ctDNA)
Technologies based on the analysis of ctDNA can be
mainly classified as targeted or untargeted (Table 1). Tar-
geted approaches are used to analyze single nucleotide
mutations or structural chromosomal rearrangements in
specified genomic regions of plasma DNA and to esti-
mate the allelic frequency of a particular mutation
within a sample. For example, somatic mutation profil-
ing can be performed by quantitative or digital PCR.
Using digital PCR, ctDNA could be detected in > 75% of
patients with advanced cancers and in 48–73% of pa-
tients with localized tumors [13]. Although digital PCR-
based methods have demonstrated to have suitable clin-
ical sensitivity considering that digital PCR and BEAM-
ing (beads, emulsion, amplification, and magnetics) can
detect somatic point mutations at a sensitivity range of
1% to 0.001% [14], these technologies require prior
knowledge of the region of interest to detect known mu-
tations given the need for the PCR assay to be designed
accordingly. Furthermore, digital PCR is limited by scal-
ability for larger studies. In particular, chromosomal re-
arrangements have demonstrated an excellent sensitivity
and specificity [15, 16]. The PARE (personalized analysis
of rearranged ends) approach first requires the identifi-
cation of specific somatic rearrangements, i.e., break-
points, found in the tumor followed by the development
of a PCR-based assay for the detection of these events in
cfDNA [15]. As these genomic rearrangements are not
present in normal human plasma or tissues unrelated to
the tumor, their detection has a high specificity and sen-
sitivity. A downside of this approach is that such rear-
ranged sequences must not be driver events and may get
lost during a disease course and therefore may not re-
flect the evolution of the tumor genome [15, 16].
Therefore, several NGS-based strategies have been de-
veloped not for targeting single or a few specific muta-
tions, but rather for selected, predefined regions of the
genome by employing gene panels. In principle, any gene
panel can be applied to cfDNA; however, in order to in-
crease resolution for mutations occurring with low allele
frequency, special technologies have been developed. TAm-
Seq (tagged amplicon deep sequencing) amplifies entire
genes by tiling short amplicons using a two-step
amplification and produces libraries tagged with sample-
specific barcodes [17]. Through this method, the detec-
tion of cancer-specific mutations down to allele
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frequencies as low as 2% and of known hotspot muta-
tions in EGFR and TP53 down to approximately 0.2%
has been reported [17, 18]. The CAPP-Seq (cancer per-
sonalized profiling by deep sequencing) method was ap-
plied to patients with non-small cell lung cancer
(NSCLC) and detected ctDNA in 100% of stage II–IV
NSCLC patients as well as in 50% of stage I patients
[19].
In contrast, untargeted approaches do not depend on
a priori knowledge and aim at a comprehensive analysis
of the tumor genome. One approach involves whole-
exome sequencing, which can be adopted for sequencing
of cfDNA for the identification of clinically actionable
mutations [20]. Whole-genome sequencing of plasma
DNA allows the comprehensive characterization of
structural variations and somatic copy number alter-
ations (SCNAs) [21–24]. These assays have similarities
to “digital karyotyping”, which involves digital enumer-
ation of observed so-called “tag sequences” from specific
genomic loci along each chromosome [25]. Such a read-
depth analysis by “tag-counting” has been the underlying
principle for the implementation of whole-genome se-
quencing approaches using plasma DNA to identify copy
number changes associated with tumor genomes [21, 22,
24, 26–29]. Interestingly, for SCNA applications, a shal-
low sequencing depth of approximately 0.1–0.2× is suffi-
cient for analyses [22].
Circulating tumor cells (CTCs)
A second approach to liquid biopsy research examines
whole tumor cells in the bloodstream, known as CTCs
[30, 31]. The first account of the existence of CTCs in
the blood came from Thomas Ashworth in 1869, much
earlier than the first mentioning of cfDNA, in which
he postulated that these cells might potentially shed
light onto the mystery behind metastases in an individ-
ual with cancer. Although a multitude of devices for
isolation of CTCs have been described [30, 32], only
the CellSearch system (Janssen Diagnostics) has been
approved by the FDA to date. Previously, it was
thought that enumeration of tumor cells in the blood
could be used alone as a barometer to measure the
level of aggressiveness of a particular cancer; however,
improvement of NGS and isolation methodologies has
allowed analyses of DNA and RNA from isolated cells
in order to gain insight into cancer driver genes
(Table 1). Since single-CTC analyses have provided
evidence of genetic heterogeneity at the level of an
individual cell, many studies have investigated their
diagnostic potential and application in cancer manage-
ment [33–39].
A strength of CTC analyses is that, as a single-cell ap-
proach, not only pure tumor DNA but also pure tumor
RNA can be obtained. This greatly facilitates the analyses
of splice variants, which, for example, play an important
role in the development of resistance to androgen
deprivation therapies in men with prostate cancer [35, 40].
Exosomes
A third target of liquid biopsies involves exosomes,
which are circulating vesicles harboring nucleic acids
shed by living cells as well as tumors. Exosomes can
range from 30 to 200 nm in size and can be isolated
from plasma, saliva, urine, and cerebrospinal fluid as
well as from serum [41, 42]. The exosome field has
gained recent attention since several studies have dem-
onstrated that these actively released vesicles can func-
tion as intercellular messengers [43–46]. Since they are
stable carriers of DNA, RNA, and protein from the cell
of origin (Table 1), this makes them particularly attract-
ive as biomarkers of cancer. Tumor exosomes, in par-
ticular, have been linked to the stimulation of tumor cell
growth, immune response suppression, and induction of
angiogenesis [43], and have been shown to play a role in
metastasis [47, 48]. Because tumor cells actively shed
tens of thousands of vesicles a day, it has been estimated
that hundreds of billions of vesicles can be found in a
milliliter of plasma [45]. Moreover, exosomes can harbor
RNA with tumor-specific mutations [43, 45, 49] and
DNA originating from these vesicles can be used to de-
tect both gene amplifications and mutations [45, 49].
Importantly, exosomes may have the potential to detect
very early cancer stages, as recently shown in patients with
pancreatic cancer [50]. Using mass spectrometry analyses,
glypican-1 (GPC1) was identified as a cell surface proteo-
glycan, which was specifically enriched on cancer-cell-
derived exosomes. GPC1+ circulating exosomes carried
specific KRAS mutations distinguishing healthy subjects
and patients with a benign pancreatic disease from pa-
tients with early- and late-stage pancreatic cancer. Fur-
thermore, these exosomes allowed the reliable detection
of pancreatic intraepithelial lesions at very early stages
despite negative signals by magnetic resonance imaging,
which may enable curative surgical interventions in this
otherwise dismal disease [50].
Mutation baseline value in healthy individuals
A great promise attributed to liquid biopsies is their pos-
sible potential to detect cancer early or even to detect
precursor lesions before clinical signs occur or before
sophisticated imaging systems are able to detect them.
However, a major problem is the number of somatic
mutations that occur in healthy individuals.
The question regarding what constitutes typical som-
atic variation and to what extent does it take form in
terms of phenotype has gained attention by recent land-
mark large-scale studies [51, 52]. Interestingly, it is pos-
sible for healthy individuals to harbor disadvantageous
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variants without exhibiting any apparent disease pheno-
type [51, 52]. In fact, the identification of rare homozy-
gotes that predicted loss of function genotypes revealed
that loss of most proteins is relatively harmless to the
individual [52]. The Exome Aggregation Consortium
study analyzed high-quality exome sequencing data from
60,706 individuals of diverse geographic ancestry and
identified 3230 genes highly intolerant to loss-of-function.
Interestingly, 72% of these genes have no established hu-
man disease phenotype yet [51]. Thus, despite our grow-
ing knowledge about the human genome, identified
variants require cautious interpretation with respect to the
potential consequences for the phenotype.
In the context of cancer and according to the somatic
mutation theory of cancer [53], malignant diseases are,
to a large extent, the result of acquired genetic and epi-
genetic changes, which has now been extensively con-
firmed by NGS technologies [54, 55]. However, a
tremendous challenge is the measurement of the somatic
mutation rate in normal tissue and establishment of
baseline values, i.e., what number of mutations is normal
for a healthy person at a certain age. In general, somatic
mutation rates are higher than germline mutation rates.
For example, it is estimated that, in humans, the per
generation rate in intestinal epithelium or fibroblasts/
lymphocytes is approximately 13- and 5-fold, respect-
ively, greater than in the germline [56].
As somatic mutations occur in individual cells, each
mutation represents a low frequency event and special
NGS methods for detection of such rare mutations are
needed. Promising approaches include single cell gen-
omic sequencing [6, 34, 57–59] and applications of mo-
lecular barcodes [60, 61]. The bottleneck sequencing
system is a novel technology that allows the quantifica-
tion of somatic mutational load in normal human tis-
sues, even at a genome-wide level [62]. The bottleneck is
created by dilution of a sequencing library before PCR
amplification, resulting in random sampling of double-
stranded template molecules. This increases the signal of
a rare mutation compared to wild-type sequences and
thus enables the detection of mutations occurring at 6 ×
10–8 per base pair. With this approach, it was shown
that, in normal colonic epithelium, mutation rates in in-
dividuals over 91 years of age had increased by an aver-
age of 30-fold in mitochondrial DNA and 6.1-fold in
nuclear DNA [62]. Importantly, the spectra of rare mu-
tations in normal colon and kidney tissues were similar
to those of the corresponding cancer type [62], confirm-
ing previous reports that cancer-associated mutations
may also occur in normal stem cells [63, 64].
Thus, direct measurements of mutations in adult
stem cells are necessary, as the gradual accumula-
tion of mutations in adult stem cells is thought to
have an especially large impact on the mutational
load of tissues due to their potential for self-
renewal and capacity to propagate mutations to
their daughter cells [63]. Indeed, statistical analyses
have recently suggested that the total number of divi-
sions of adult cells needed to maintain tissue homeo-
stasis correlates with the lifetime risk of cancer [63].
However, these calculations could not exclude extrin-
sic risk factors as additional important determinants
for cancer risk [65].
Measurement of the somatic mutation load in stem
cells within various human tissues poses an immense
technical problem. Blokzijl et al. [66] addressed this
challenge by using cells capable of forming long-term
organoid cultures. An organoid can be defined as a
cellular structure containing several cell types that
have developed from stem cells or organ progenitors
that self-organize through cell sorting and spatially re-
stricted lineage commitment [67]. Single adult stem
cells from the small intestine, colon, and liver, tissues
which differ greatly in proliferation rate and cancer
risk, were expanded into epithelial organoids to ob-
tain sufficient DNA for whole-genome sequencing.
The donors ranged in age from 3 to 87 years and,
not unexpectedly, it was found that stem cells accu-
mulated mutations with age independent of tissue
type [66]. The mutation rate, i.e., the increase in the
number of somatic point mutations in each stem cell,
was in the same range for all assessed tissues, at ap-
proximately 36 mutations per year, despite the large
variation in cancer incidence among these tissues
(Fig. 1a). Importantly, the findings suggested a univer-
sal genomic ageing mechanism, i.e., a chemical
process acting on DNA molecules, independent of
cellular function or proliferation rate. Furthermore,
this intrinsic, unavoidable mutational process can
cause the same types of mutations as those observed
in cancer driver genes [66].
Given the high mutation rate in adult stem cells, it
may be surprising that cancer incidence is not actu-
ally higher. According to the “Three Strikes and
You’re Out” theory [68] (Fig. 1b), alterations in as
few as three driver genes may be sufficient for a cell
to evolve into an advanced cancer. However, several
reasons may account for the relatively low cancer in-
cidence. First, mutations in stem cells are non-
randomly distributed and associated with depletion in
exonic regions. Second, if a mutation occurs in an ex-
onic region, it has to be in a cancer driver gene and
only a small number of genes in the human genome
have been shown to act as driver genes [69]. Third,
the order in which driver gene mutations accumulate
is important, meaning that mutations which are initi-
ating events have to occur first [68]. Fourth, many of
the initiating driver gene mutations are tissue specific;
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thus, the driver gene mutation must occur in the right
gene and not in any driver gene.
In light of these findings, it is not surprising that
cancer-associated mutations might be identified in
plasma DNA from healthy persons. This was shown
in a recent study that used an assay specifically de-
signed to accurately detect TP53 mutations at very
low allelic fractions, in which cfDNA TP53-mutated
fragments were found in 11.4% of 123 matched non-
cancer controls [70] (Fig. 1c). However, the detection
of low-allele variants may be impeded by background
errors occurring during library preparation and/or
sequencing. To address this, approaches such as molecular
barcoding and background reduction by sophisticated
bioinformatics methods have been developed, as is dis-
cussed below.
New liquid biopsy technologies and emerging
concepts
Improved low-frequency allele detection
One of the biggest technical challenges to overcome in
the analysis of cfDNA is the issue of low-frequency mu-
tant alleles since ctDNA levels vary greatly among pa-
tients and can reach as low as 0.01% of the total cfDNA
in patients with early-stage disease [7, 10]. Although
massively parallel sequencing technologies in principle
offer the capacity of detecting these singled out rare
variants, the error rate of sequencing instruments is typ-
ically a limiting factor for accurately calling these vari-
ants. Therefore, the application of molecular barcodes
has received much warranted attention in the last few
years [17, 19, 60, 61] and the resolution may be further
increased by bioinformatics approaches.
Fig. 1 Mutation rate in adult stem cells and their potential consequences. a Correlation of the number of somatic point mutations in adult stem cells
derived from colon, small intestine, and liver with age of the donor (adapted from [66]); there is an increase of ~36 mutations/adult stem cell/year. b
Summary of the “Three strikes to cancer model” [68] for colorectal cancer, where mutations occur in specific driver genes. In the breakthrough phase, a
mutation occurs in APC and results in abnormal division of the respective cell. Subsequently, a mutation in KRAS may follow in the expansion phase
and may give rise to a benign tumor. Occurrence of a further mutation in a driver gene in at least one of the listed pathways SMAD4, TP53, PIK3CA, or
FBXW7 may enable the tumor to invade surrounding tissues and to initiate the invasive phase with dissemination of tumor cells and formation of
metastases [68]. The mutations may be detectable in cfDNA; furthermore, depending on the ctDNA allele frequency and tumor stage, somatic copy
number alterations may become visible (shown exemplarily for chromosome 8: blue: lost; green: balanced; and red: gained region). c As the order of
driver gene mutations is important, the consequences differ if a TP53 mutation occurs in a colon stem cell before the initiating mutations have taken
place. Such a TP53 mutation alone will not be sufficient to cause increased proliferation or even to transform the cell into a tumor cell. However, due
to the stem cell’s capacity of self-renewal, cells with this mutation may be propagated in the respective part of the colon. Depending on how many of
these cells are removed by apoptosis or other events, ultra-sensitive ctDNA assays may then detect this mutation in the blood; this will usually not be
accompanied by copy number alterations (as indicated by the green scatter-plot for chromosome 8)
Perakis and Speicher BMC Medicine  (2017) 15:75 Page 5 of 12
For example, Newman et al. [71] expanded on their
existing CAPP-Seq method by adding a molecular bar-
code approach and by incorporating an in silico bio-
informatics strategy to reduce background noise, which
they dubbed “integrated digital error suppression”. They
were able to increase the sensitivity of the original
CAPP-Seq method by 15-fold and reported a sensitivity
and specificity of 92% and 96%, respectively, when pro-
filing EGFR kinase domain mutations in cfDNA of
NSCLC samples. However, it must be considered that a
typical plasma sample of 1 mL contains approximately
3000 copies of each gene, implicating a sensitivity limit
of detecting only 1 in 15,000 copies from a 5-mL sample
[72]. Including statistical sampling errors, the available
genome equivalents of clinical samples will be an im-
portant determinant of possible resolution limits in
ctDNA analyses.
Nevertheless, novel commercial products, including mo-
lecular barcodes, are being offered by industry providers
(e.g., ThruPLEX® Tag-seq, Rubicon Genomics; HaloPlexHS,
Agilent; QIAseq Targeted DNA Panels, Qiagen) and may
help to make these sophisticated technologies broadly
available. Another large-scale initiative known as GRAIL
(www.grailbio.com) vows to detect cancer so early that it
can be cured. This ambitious aim is supposed to be
accomplished by efforts including ultra-broad and ultra-
deep sequencing, bioinformatics, and large population-
based clinical studies [73].
Epigenetics: plasma bisulfite sequencing and nucleosome
mapping
Of especial interest are studies of cfDNA methylation pat-
terns, since plasma contains a mixture of DNA from dif-
ferent tissues and organs. As certain methylation patterns
are tissue specific, they could serve as an epigenetic signa-
ture for the respective cells or tissues that release their
DNA into the circulation. Such efforts greatly benefit from
reference methylomes of multiple tissue types provided by
the International Human Epigenome Consortium. For ex-
ample, “plasma DNA tissue mapping” is an approach
employing genome-wide bisulfite sequencing of plasma
DNA and methylation deconvolution of the sequencing
data to trace the tissue of origin of plasma DNA in a
genome-wide manner [74]. In order to increase the signal-
to-noise ratio of such assays, stretches of four to nine
CpG sites adjacent to the tissue-specific methylation
marker site can be used [75] (Fig. 2a). Indeed, such a pro-
cedure may achieve sensitivities suitable not only for can-
cer detection but also for other clinical conditions such as
type I diabetes, multiple sclerosis, acute brain damage fol-
lowing cardiac arrest, or traumatic brain injury [75].
A recent study took a very different approach to
whole-genome sequencing and leveraged the fact that
plasma DNA is nucleosome-protected DNA. This is
reflected in the genomic sequencing coverage of plasma
DNA fragments around transcription start sites (TSSs),
as read depth was lower and had distinct coverage
patterns around the TSSs of housekeeping genes and
other highly expressed genes. The sequencing coverage
differed from unexpressed genes, which are densely
packed by nucleosomes [76] (Fig. 2b). In fact, nucleo-
some positions inferred from whole-genome sequencing
of plasma DNA strongly correlated with plasma RNA
levels in cancer-free subjects. Furthermore, in plasma of
patients with cancer the expression levels of genes in the
corresponding tumor were reflected by the coverage
around the TSSs [76].
In addition, Snyder et al. [77] also recently identified a
direct association between cfDNA and nucleosome posi-
tioning and similarly demonstrated that cfDNA levels
and fragment sizes reflected the epigenetic features char-
acteristic of lymphoid and myeloid cells. These current
studies both expand on the potential of using ctDNA
analysis for other applications rather than just mutation
or SCNA analysis. New possibilities arise from these
findings such as the investigation of a patient’s individual
cancer transcriptome, tracking changes in gene isoform
expression during treatment, or even helping identify
the tissue of origin in cancers which the primary tumor
is unknown [78].
Plasma RNA analyses
Plasma cell-free RNA has been investigated for a long
time [79, 80]; however, the comprehensive RNA analyses
to establish landscapes of cell-free RNA transcriptomes
either by microarrays or by RNA sequencing (RNA-seq)
is relatively novel (Fig. 2c). These technologies are prom-
ising as they can provide insights into the temporal dy-
namics of plasma mRNA and, furthermore, analyses of
tissue-specific genes allows for estimation of the relative
contributions of tissues that contribute circulating RNA.
This may enable monitoring of some developmental or
disease states of certain tissues; for example, cell-free
RNA patterns were longitudinally analyzed in pregnant
women and after delivery [81, 82]. However, RNA tran-
scription can vary between people with different vari-
ables such as sex, age, or certain diseases. Therefore,
carefully annotated health control libraries from individ-
uals with various health conditions are needed for com-
parison of diseases such as cancer [83].
Novel plasma DNA preparation protocols
In most protocols, cfDNA is adapted for sequencing via
ligation of double-stranded DNA adapters. However, re-
cent studies have provided evidence that ctDNA is
shorter than cfDNA from non-tumor cells [84, 85]. As
double-stranded DNA library preparations are relatively
insensitive to ultrashort, degraded cfDNA, it has been
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suggested that single-stranded DNA library preparation
may represent an alternative and may yield increased pro-
portions of smaller (<100 bp) cfDNA fragments [77, 86]
(Fig. 2d). In addition to a proportional ctDNA increase,
single-stranded sDNA cfDNA libraries also contain
elevated mitochondrial and microbial-derived cfDNA [86]
and may therefore offer further options for cfDNA
analyses.
Emerging novel exosome technologies
At present, specific detection and isolation of cancer
cell-derived exosomes in the circulation is lacking. It
is conceivable that mass spectrometry analyses may
further identify cell surface markers, such as the
aforementioned GPC1 [50], to improve enrichment of
cancer cell-derived exosomes. Together with specific
mutations, exosomes may then be used, not only to
monitor disease courses, but also to detect early
stages of cancers.
However, detection and molecular profiling of exosomes
remains technically challenging. Recent approaches for
high-throughput quantitative analyses of exosomes
employing arrays functionalized with antibodies to en-
able profiling of exosome surface proteins and proteins
Fig. 2 Summary of some emerging technologies in the liquid biopsy field. a Plasma DNA tissue mapping: Plasma DNA tissue mapping is an
approach employing genome-wide bisulfite sequencing of plasma DNA and methylation deconvolution of the sequencing data to trace the tissue of
origin of plasma DNA in a genome-wide manner (here shown exemplarily for liver-specific markers). The signal-to-noise ratio of such assays can be
increased by the analysis of stretches of several CpG sites adjacent to the tissue-specific methylation marker. b Nucleosome mapping: analysis of the
genomic sequencing coverage of plasma DNA fragments reveals the position of nucleosomes because plasma DNA is nucleosome-protected DNA. At
transcription start sites (TSSs; indicated by a gray arrow), in particular at the nucleosome depleted region, the read depth is lower and has distinct
coverage patterns around the TSSs of highly expressed genes (shown in blue), which differs from coverage patterns of unexpressed genes (red). c
Plasma RNA-seq: After extraction of cell-free RNA from plasma and DNase I digestion, cDNA is synthesized and amplified from cell-free
RNA. Deconvolution of the cell-free transcriptome using microarrays is conducted to determine the relative RNA contributions of certain
tissues in a sample based on known tissue-specific expression profiles. In parallel, selected transcripts are quantified by qPCR (procedure
based on [81]). d Single-stranded DNA (ssDNA) library preparation: the scheme illustrates the key steps in the ssDNA ligation procedure.
The ssDNA (top panel), which is not size-selected to avoid elimination of shorter fragments, is ligated to biotinylated probes (second
panel), and after ligation of double stranded primers, extended to double-stranded DNA (third panel). DNA molecules of different lengths
with a lower limit of efficient capture of approximately 40–60 bp can be obtained (adapted from [86]). e CTC-derived explants (CDXs): The patients’
blood is enriched for CTCs (green cells in top panel) and injected into one or both flanks in mice (second panel). The obtained CDXs (brown tumor in
third panel) are then analyzed by histopathology, immunohistochemistry, and genomic analyses to confirm that characteristics of the original tumor
were maintained. Mice bearing CDXs can be treated to evaluate response to various agents
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present in exosome lysates may greatly facilitate the
diagnostic potential of exosomes [87].
Functional CTC studies and CTC-derived explants
Functional CTC studies are highly challenging because of
the low number of CTCs that can be retrieved from pa-
tient blood. The development of novel CTC culturing
technologies is extremely promising in this regard. One
study demonstrated that CTCs from chemotherapy-naïve
patients with extensive-stage metastatic small cell lung
cancer (SCLC) are tumorigenic in immunocompromised
mice [88] (Fig. 2e). Patients’ blood was enriched for CTCs
and injected into one or both flanks in mice. CTC-derived
explants (CDXs) resulted in samples derived from patients
with high CTC numbers (>400 CTCs per 7.5 mL). Histo-
pathology and immunohistochemistry confirmed that
CDXs represented clinical SCLC, and detailed analyses of
their genomes demonstrated that previously described
characteristics of SCLC were maintained [88]. The re-
sponse of CDXs to therapy closely mirrored overall sur-
vival of the corresponding patients [88].
In fact, the generation of cell lines from CTCs is an
exciting novel field. Recently, the establishment of CTC
lines from patients with colon cancer [89] and breast
cancer [36, 90] were reported. In prostate cancer, a 3D
organoid system allowed the development of a long-
term CTC culture [91]. Perhaps one of the most exciting
applications of CTC lines is that CDXs may support se-
lection of targeted therapies and may evolve to instru-
mental tools for drug development. More detailed
analyses of CDXs lines, perhaps as recently demon-
strated for patient-derived tumor xenografts [92], are
warranted to further investigate the potential of this
approach.
Challenges for liquid biopsy applications and how
close are we to the clinic
In particular, a more mature understanding of the biol-
ogy behind ctDNA, CTCs and exosomes will help us
understand if the molecular profiles generated from
these sources truly reflect the physiological disease state
of the patient and if they can help physicians reliably de-
tect and monitor the disease. In order to confirm this,
we must uncover the origin and dynamics of these
tumor parts in the circulation and furthermore, deter-
mine their biological significance and clinical relevance.
Although the exact mechanisms behind the release
and dynamics of cfDNA remain unknown, several hy-
potheses exist to explain the existence of tumor DNA in
the bloodstream. Perhaps the most widely accepted the-
ory is that tumor cells release DNA via apoptosis, necro-
sis, or cell secretion in the tumor microenvironment [14,
93, 94]. Some cancer cases examined had detectable
ctDNA levels but no detectable levels of CTCs [13]. Vice
versa, a patient with an excessive number of CTCs of
more than 100,000 was described, who, despite of pro-
gressive disease, had a low ctDNA allelic frequency in
the range of merely 2–3% [26]. While in most patients
CTC number and ctDNA levels are mutually correlated
[26], such cases illustrate that exceptions exist and that
the underlying biology of both CTC and ctDNA release
is still poorly understood.
Other basic unknowns regarding liquid biopsy imple-
mentation in the clinic revolve around questions of
whether or not ctDNA does actually indeed offer a full
representation of a patient’s cancer, if all existing metas-
tases contribute to the ctDNA, CTCs, and exosomes
found in the bloodstream, or if all tumor cells release an
equal amount of ctDNA into the circulation. In order to
establish to what extent ctDNA represents metastatic
heterogeneity, one study followed a patient with meta-
static ER-positive and HER2-positive breast cancer over
3 years [95]. The genomic architecture of the disease
was inferred from tumor biopsies and plasma samples
and, indeed, mutation levels in the plasma samples sug-
gested that ctDNA may allow real-time sampling of
multifocal clonal evolution [95]. Conduction of warm
autopsies, i.e., rapid tumor characterization within hours
of death, might further help answer these questions
more fully, as data derived from the tumor post-mortem
could be compared to previously collected ctDNA from
the patient [96].
It has furthermore been demonstrated that the per-
centage of ctDNA within total cfDNA can vary greatly
between patients from less than 10% to greater than 50%
or, as suggested more recently, can even be detected at
fractions of 0.01% [13, 19, 97]. However, despite this
high variability in ctDNA levels in different cancer pa-
tients, numerous studies have shown that intra-patient
levels correlate with both tumor burden and progression
of disease [14, 17–20, 27, 29, 98–102], giving evidence
for the use of ctDNA levels as a proxy measurement of
tumor progression and response to therapy. Accordingly,
in colorectal cancer, ctDNA analyses revealed how the
tumor genome adapts to a given drug schedule and li-
quid biopsies may therefore guide clinicians in their de-
cision to re-challenge therapies based on the EGFR
blockade [98]. For patients with NSCLC, the Food and
Drug Administration approved the implementation of
cfDNA in EGFR mutation analysis, through a test called
the “cobas EGFR Mutation Test v2” (Roche), which
serves as the first blood-based companion diagnostic to
test which patients are potential candidates for the drug
Tarceva (erlotinib). In a very recent study [103], this kit
was used to confirm that patients treated with first-line
EGFR tyrosine kinase inhibitor had acquired the EGFR
T790M (p.Thr790Met) mutation, which confers resist-
ance to first-generation EGFR tyrosine kinase inhibitors
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[103]. The authors then showed that NSCLC patients
with this T790M mutation who were treated with osi-
mertinib had better response rates and progression-free
survival than patients treated with platinum therapy
[103]. This is a beautiful example in which an invasive
lung tissue biopsy was replaced by a plasma DNA-based
blood test, i.e., a liquid biopsy, to identify a group of pa-
tients who could benefit from a specific treatment. This
will likely propel development of further NGS-based
EGFR mutation detection assays, which are of particular
relevance for the Asian population in which EGFR
mutation-positive lung cancers occur more frequently
than in the Caucasian population [104].
However, before liquid biopsies can serve as viable
diagnostic assays, pre-analytical steps, such as the collec-
tion of biofluid (e.g., blood, serum, plasma), centrifugation
settings, isolation reagents, and storage conditions, must
be standardized in order to ensure reproducible process-
ing procedures. Furthermore, analytical steps, such as
quantification of cfDNA and subsequent mutational ana-
lysis, i.e., the NGS assay and sequencing platform itself,
must be validated to simulate clinical settings. In addition,
sensitivities and specificities of the applied assays must be
robust, reproducible, and have the appropriate internal
and external quality controls [72]. Perhaps the most im-
perative step is the need to evaluate the clinical relevance
of ctDNA at various time points depending on the appli-
cation, such as patient stratification, evaluation of treat-
ment response, efficacy, and resistance, as well as
validating this data in large multicenter clinical studies
[72]. Furthermore, the clinical performance of cfDNA as-
says must satisfy the requirements of the respective regu-
lative agencies, such as Clinical Laboratory Improvement
Amendments in the USA or the genetic testing practices
in European countries. In Europe, efforts to harmonize li-
quid biopsy testing are supported by CANCER-ID, a
European consortium supported by Europe’s Innovative
Medicines Initiative, which aims at the establishment of
standard protocols for and clinical validation of blood-
based biomarkers (www.cancer-id.eu/).
Conclusions
Cancer is a complex, heterogeneic, and dynamic disease
involving multiple gene-environment interactions and
affects numerous biological pathways. As such, the de-
velopment of reliable and robust non-invasive platforms
represents a vital step towards the promise of precision
medicine. Current work in the liquid biopsy field con-
tinues to show great potential utility in the diagnosis
and stratification of cancer patients and furthermore ex-
emplifies a surrogate method for monitoring treatment
response when compared to the tissue biopsy approach.
The ease and frequency made possible by serial liquid
biopsy collection offers plenty of advantages compared
to standard surgical procedures, especially including the
opportunity of more rapid course correction of adminis-
tering therapies. As technological advances continue and
further innovations in liquid biopsy methodology arise
in parallel, this approach will hopefully enable methods
for pre-diagnostic assessment of cancer risk as well. As
our knowledge of the biology behind cfDNA improves,
so too will the management of cancer patients as the li-
quid biopsy method becomes one of clinical reality.
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